|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B related cirrhosis.
|
31574141 |
2020 |
|
LGALS3BP
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
|
30918432 |
2019 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, whether serum glycosylation isomer of M2BP (M2BPGi) was associated with the regression of liver fibrosis in patients with chronic hepatitis B (CHB) during IFN-α add-on therapy is still unknown.
|
30905065 |
2019 |
|
LGALS3BP
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate WFA+-M2BP level in assessing liver fibrosis in patients with chronic hepatitis B (CHB) infection.
|
31393964 |
2019 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
|
30786068 |
2019 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.
|
29611385 |
2018 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mac-2 binding protein glycosylation isomer (M2BPGi) is an emerging biomarker for risk prediction of liver disease, but data remain sparse for patients with chronic hepatitis B (CHB) who are treated with nucleos(t)ide analogues (NA).
|
30306612 |
2018 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
|
28849280 |
2018 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi), a novel serum marker for liver fibrosis, was seldom studied in chronic hepatitis B (CHB).
|
29915243 |
2018 |
|
LGALS3BP
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum WFA<sup>+</sup> -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.
|
27300763 |
2017 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment.
|
28537900 |
2017 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B.
|
26990490 |
2017 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated whether serum WFA<sup>+</sup> -M2BP can predict the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.
|
27973711 |
2017 |
|
LGALS3BP
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
|
27029022 |
2017 |